What is Transomic Technologies?
Transomic Technologies is a key player in the life science research tools market, offering an extensive portfolio of lentiviral-based functional genomics solutions. Leveraging cutting-edge technologies like CRISPR-Cas9, the company empowers researchers to accelerate discovery. Transomic also engages in custom service projects for major pharmaceutical entities, developing critical resources such as knockout cell lines and CRISPR screening assays, thereby facilitating advancements in drug development and biological understanding.
How much funding has Transomic Technologies raised?
Transomic Technologies has raised a total of $375K across 1 funding round:
Private Equity
$375K
Private Equity (2022): $375K with participation from Immunotherapy
Key Investors in Transomic Technologies
Immunotherapy
Immunotherapy is a clinical-stage biotechnology company focused on developing innovative treatments that leverage the body's natural mechanisms for a broad range of diseases.
What's next for Transomic Technologies?
The substantial late-stage funding indicates Transomic Technologies is poised for significant expansion and further integration of its advanced genomic tools into the pharmaceutical and biotechnology research pipelines. This capital infusion is expected to fuel continued innovation in CRISPR-based technologies and broaden the company's service offerings to a global client base, solidifying its role as a critical partner in scientific advancement.
See full Transomic Technologies company page
